BD, Fujirebio Partner on Cancer Dx Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson and Fujirebio Diagnostics have inked a worldwide development and supply agreement for multiplex oncology diagnostic assays.

The firms said today that they will develop diagnostic products that contain Fujirebio's biomarkers that will run on BD's multiplex testing platform. Initial efforts will focus on the ovarian cancer biomarker HE4, which is cleared by the Food and Drug Administration for monitoring the progression or recurrence of epithelial ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.